Better Health for All

TherapeuticsMD's core business, as a pharmaceutical royalty company since December 30, 2022, involves licensed products focused on women's health, including IMVEXXY for menopausal symptoms, BIJUVA for vasomotor symptoms, ANNOVERA for contraception, and prenatal vitamins.

These products provide substantial health benefits, with no evidence of products causing significant negative health outcomes. The prenatal vitamins are gluten-, sugar-, and lactose-free, with vegan and kosher options. ANNOVERA is a patient-controlled contraceptive, and prenatal vitamins contribute to preventative health. The company explicitly discloses health risks, including boxed warnings for IMVEXXY, BIJUVA, and ANNOVERA, and lists contraindications and warnings in product labeling. However, the company ceased all research and development activities as of December 30, 2022. For clinical trials, the company adheres to cGCPs, requires informed consent, and obtains IRB approval, but FDA required post-approval observational studies for IMVEXXY and ANNOVERA to evaluate specific risks. Manufacturing facilities for IMVEXXY, BIJUVA, and vitaTrue received FDA Form 483 observations in 2018, and Catalent received another in 2019, which was later classified as 'Voluntary Action Indicated'. The company offers co-pay assistance programs for IMVEXXY, with 90% of patients enrolled, and provides reduced pricing for ANNOVERA to federally designated Title X family planning clinics serving underrepresented women. However, ANNOVERA has not been adequately studied in females with a BMI >29 kg/m2. The company granted a royalty-free license for a generic BIJUVA to Amneal commencing in May 2032, 180 days before patent expiration in November 2032, and ANNOVERA has five years of regulatory exclusivity.

Fair Money & Economic Opportunity

TherapeuticsMD, Inc. is a pharmaceutical company focused on developing and commercializing women's health products.

Its core business activities, including research, development, manufacturing oversight, sales, and marketing of prescription pharmaceuticals, do not involve lending, insuring, moving, or storing money for consumers. As such, the provided articles contain no specific, concrete data points relevant to the KPIs under the 'Fair Money & Economic Opportunity' value, which primarily assesses financial institutions and their services. Therefore, all KPIs are omitted due to a lack of applicable evidence.

Fair Pay & Worker Respect

Employee satisfaction, based on an overall rating from 20 reviews, stands at 3.2 out of 5 stars (64%).

No specific quantitative data is available for living wage coverage, CEO-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.

Fair Trade & Ethical Sourcing

No specific quantitative data for TherapeuticsMD, Inc. (TXMD.US) regarding fair trade certifications, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend is provided in the available articles.

The articles discuss general sustainability and ethical sourcing policies of Mayne Pharma but explicitly state the absence of company-specific metrics for TXMD.US.

Honest & Fair Business

The provided article states that TherapeuticsMD, Inc. was charged by the SEC for selectively disclosing information from an FDA meeting.

However, the article does not provide any specific financial penalties, dates within the last three years, or other quantitative data related to ethical performance, transparency benchmarks, policies, or governance metrics required by the rubric's KPIs. Therefore, no KPIs can be scored based on the available evidence.

Kind to Animals

TherapeuticsMD launched one product, a prescription prenatal multivitamin, that is certified vegan and contains plant-based DHA.

However, the company's 10-K filing indicates that preclinical animal studies are required by the FDA for new drug products, suggesting a reliance on animal testing for its pharmaceutical portfolio. The company's public policy engagement focuses on monitoring potential impacts of proposals to change prescription drug costs at the federal and state level, with no mention of animal welfare legislation or standards.

No War, No Weapons

No information was found in the provided articles regarding TherapeuticsMD, Inc.'s involvement in arms manufacturing, military contracts, conflict facilitation, or any related activities.

Therefore, no assessment can be made against the 'No War, No Weapons' ethical value.

Planet-Friendly Business

TherapeuticsMD, Inc. does not disclose any sustainability data, making it impossible to assess its planet-friendly business practices.

The company is not participating in any tracked initiatives, and no specific data is publicly available for any of the environmental KPIs.

Respect for Cultures & Communities

The provided articles, primarily financial reports and general company information, do not contain specific, concrete data points or actions related to TherapeuticsMD's engagement with cultures and communities. There is no evidence regarding formal partnerships with indigenous or local community groups, reinvestment in local community development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, grievance mechanisms, FPIC processes, community governance inclusion, cultural preservation investment, local procurement, indigenous suppliers, cultural site protection, social license, charitable giving to cultural organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training completion.

Therefore, no KPIs can be scored based on the available information.